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Abstract 
Background: Changes in relation to drug treatment to various control targets for diabetes were 
studied using the National Health and Nutrition Examination Survey (NHANES) 1999-2010.  
Methods: Data on 3094 participants aged ≥20 with diagnosed type 2 diabetes were analyzed. Use 
of medications for lowering glucose, blood pressure, and lipids in the past month was assessed by 
questionnaire. Data from two survey cycles were combined together to produce estimates for each 
four-year period. 
Results: Usage of metformin increased from 34.8% to 53.8% and was the most prevalent 
medications during this period (P<0.001), and half of subjects taking metformin could achieve 
HbA1c <7.0% in 2007-2010. Dipeptidyl peptidase-4 (DPP-4) inhibitors, were used by 7.4% of 
participants in 2007-2010. Usage of angiotensin receptor blockers (ARB) and beta-blockers 
increased significantly from 7.4% to 21.4% and from 15.3% to 31.8%, respectively from 1999-2010 
(P≤0.001). 64.7% of participants could attain blood pressure control by 2007-2010. Usage of statins 
doubled in 1999-2010 and 52.2% of subjects took statins by 2007-2010 (P<0.001). 
Conclusions: Metformin is the first line drug for diabetes while DPP-4 inhibitors started to be used 
since 2007. Blood pressure control improved in 1999-2010 partly due to increased drug 
prescriptions. Although statins were widely used about half of the participants did not take them. 
(209 words)  
Key words: diabetes, prescription medications, NHANES 
Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes Study; ACEI, 
angiotensin-converting enzyme inhibitor; ADA, American Diabetes Association; ARA, aldosterone 
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dipeptidyl peptidase-4; GLP-1, glucagon-like-peptide-1; HbA1c, glycated haemoglobin; HDL, High 
density lipoprotein; LDL, Low density lipoprotein; NHANES, National Health and Nutrition 
Examination Survey  
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Introduction 
  Type 2 diabetes affects more than 1 in 10 of the US population according to a recent report (1), 
and imposes a huge burden on healthcare expenses. Previous findings from the United States 
National Health and Nutrition Examination Survey (NHANES) showed that the prevalence of 
diagnosed diabetes increased significantly from 1999 to 2006 (2). Good control of glycemic and 
blood pressure targets is important in the management of type 2 diabetes. Good control of blood 
glucose and blood pressure reduces microvascular and macrovascular complications (3-5).  
  Our previous reports have evaluated the prevalence and therapeutic target achievement in the US 
adults using data from the NHANES studies (2, 6). A recent study has also shown that about 
33-48% of subjects with diabetes did not meet the targets for glycemic, blood pressure or LDL 
cholesterol control in US NHANES 1999-2010 (7). Better utilization of medications might improve 
the control of these targets. In US, eleven unique types of drugs have been approved to treat type 2 
diabetes, and 9 of them have become available since 1995 (8). New pharmacotherapies have 
become available, ranging from established agents to new drugs acting on the incretin pathway (9). 
Therefore it is necessary for clinicians to have a rational approach for the choice of therapy. 
  Although we previously investigated the achievement of glycemic, blood pressure and 
low-density lipoprotein (LDL) targets in NHANES 1999-2006 (2), utilization of medications in 
people with diabetes has not been updated. The present study provides an update on the utilization 
of prescribed medications for lowering blood glucose, lipids and blood pressure from 1999 to 2010.  
 
Methods 
Study design and subjects 
  NHANES was conducted by the National Center of Health Statistics, Centers for Disease Control 
and Prevention, with a stratified, multistage probability sampling design (10). Written informed 
consent was obtained from all participants. In NHANES 1999-2010, there were 30,752 subjects 
aged ≥20 years who were both interviewed and examined in the mobile examination center. After 
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excluding all pregnant women and subjects with missing data, 28,774 subjects were included in the 
analysis. Among them, 3,168 subjects had self-reported diagnosis of diabetes. Subjects who 
answered “yes” to the interview question “Other than during pregnancy, have you ever been told by 
a doctor or health professional that you have diabetes or sugar diabetes?” were categorized as 
having diagnosed diabetes. In NHANES, diabetes was not classified into type 1 or 2, therefore 74 
participants with diabetes diagnosed at age < 30 years and treated with insulin alone were further 
excluded in the analysis as they were considered as having type 1 diabetes (2, 11). Therefore, a total 
of 3,094 subjects were included in this analysis.   
 
Type of treatment and prescription medications 
  The use of prescription medications for lowering blood lipids, glucose, and blood pressure in the 
past month was assessed by questionnaires. Participants were asked whether they had taken or used 
any prescription medicine in the past month and showed the interviewer the medication containers 
and the exact name of all the products. If the container was unavailable, the interviewer asked the 
participants to verbally report this information. Details on the classification of the prescription 
medications have been described as previously (12, 13). A participant, who took two or more 
different classes of medications for the same therapeutic use (lowering either blood lipids, glucose, 
or blood pressure), either as a single combination pill or several different pills, was defined as 
receiving polytherapy. Participants with diagnosed diabetes who were not on medication (insulin or 
an oral anti-diabetic drug) were assumed to have non-pharmacologic therapy (diet and lifestyle 
changes).   
 
Other variables of interest 
  Information on race/ethnicity, education, history of cardiovascular diseases, smoking, alcohol 
consumption, family history of diabetes and age of diabetes diagnosis was obtained from 
self-reported questionnaires at baseline (2, 10, 12-15). Ever smokers were defined as subjects who 
5 
 
had smoked ≥100 cigarettes in their lives. Regular alcohol drinking was defined as consumption of 
any type of alcoholic beverage at least once a week in the past year. Details on the laboratory 
measurement methods of other biochemical variables have been described as previously (2, 6, 
11-15). Microalbuminuria was defined as a urinary albumin-to-creatinine ratio ≥30 μg/mg (16). 
Triglyceride levels were log-transformed before analysis 
 
Treatment goals for diagnosed diabetes 
  The definitions of different treatment goals for diagnosed diabetes were based on the recent 
American Diabetes Association (ADA) guidelines (16). Patients with diabetes should be treated 
with the glycemic, blood pressure, and lipid targets being HbA1c <7.0%, blood pressure <140/80 
mmHg, and LDL cholesterol <100 mg/dL. We also examined the secondary lipid targets, i.e. 
triglycerides <150 mg/dL, and HDL cholesterol >40 mg/dL in men and >50 mg/dL in women in a 
separate analysis. 
 
Statistical analysis 
Data analysis was performed using the complex sampling function of SPSS version 20.0 (SPSS 
Inc, Chicago, IL). Variables with skewed distribution were log-transformed before analysis.  
Examination sampling weights were used in all analyses to obtain estimates representative of the 
United States Census civilian non-institutionalized population (17). Separate fasting sampling 
weights were used for the analysis involving serum triglycerides and LDL cholesterol as they were 
measured only in subjects who were examined in the morning session and had fasted for 8-24 hours, 
To obtain more reliable estimates, data from two survey cycles were combined together to produce 
estimates for each four-year period. To analyze the trends over time, multiple logistic or linear 
regression models were used, in which survey year (1999-2002, 2003-2006 and 2007-2010) was 
included as an independent continuous variable. A two-tailed P<0.05 was considered statistically 
significant. 
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Results 
  Table 1 shows the characteristics of 3094 participants aged ≥ 20 years with diagnosed type 2 
diabetes. The majority of this population were above 40 years old and non-Hispanic whites. There 
was a significant increase in waist circumference and BMI (both P≤0.001). There was a significant 
increase in the proportion of obese people with BMI ≥30 kg/m2 from 1999-2010 (P<0.001). During 
the same period, there were significant decreases in systolic blood pressure (from 133.0 mmHg to 
128.9 mmHg, P<0.001), total cholesterol (from 208.2 mg/dL to 183.0 mg/dL, P<0.001), LDL 
cholesterol (from 117.6 mg/dL to 99.8 mg/dL, P<0.001), and triglycerides (from 160.9 mg/dL to 
133.4 mg/dL, P≤0.002).  
  Utilization of different types of medications among people with diagnosed diabetes is shown in 
Tables 2-4. Among different glucose lowering medications prescribed, metformin is the 
recommended drug for diabetes according to the ADA guideline (11). Usage of metformin 
increased significantly from 34.8% to 53.8% from 1999-2010 (P<0.001) (Table 2), and became the 
most common medication for diabetes in 2003-2010. DPP-4 inhibitors started to be used by 7.4% of 
the patients in 2007-2010. Regarding glycemic control, about half of the participants taking 
metformin could achieve glycemic target by 2007-2010 (Figure 1a). There was also a doubling in 
the proportion of subjects who took thiazolidinediones achieving glycemic control from 1999-2010 
(P=0.017). About 33.4% of people taking DPP-4 inhibitors could achieve glycemic control.  
  Increased usage of anti-hypertensive medications such as angiotensin-converting enzyme 
inhibitor (ACEI), aldosterone receptor antagonist (ARB), beta-blockers and diuretics was observed 
(P≤0.001) (Table 3). The ADA guideline recommends the use of either ARB or ACEI to treat 
subjects with both hypertension and diabetes (11). There was a significant increase in proportion of 
people taking either ARB or ACEI who could achieve blood pressure control (P=0.009) (Figure 1b). 
Significant improvement could also be seen in people taking β-blockers and people taking diuretics 
(P<0.05). Overall by 2007-2010 60% of subjects with any anti-hypertensive drug treatment could 
achieve the blood pressure target (<140/80 mmHg). 
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  Among different lipid lowering medications, statin remained the most common type of drugs 
across the 12-year period, and the proportions of subjects on statins increased significantly from 
28.5% to 52.1% (P<0.001) (Table 4). The LDL cholesterol control rate among people taking statins 
increased significantly from less than half in 1999-2002 to about three-quarters in 2007-2010 
(P<0.001) (Figure 1c). 
  Supplementary Table S1 shows the overall glycemic, blood pressure and LDL cholesterol control 
rates in 1999-2010. During the 12-year period, the glycemic control rate increased significantly. 
Using the revised blood pressure target of <140/80 mmHg, blood pressure control rate increased 
significantly from 55.2% to 64.7% (P=0.002). There was also a significant increase in LDL 
cholesterol control rate from 35.0% to 56.5% across the same period (P<0.001). The overall 
proportion of people achieving all the glycemic, blood pressure and LDL cholesterol target levels 
increased from 8.7% in 1999-2002 to 24.0% in 2007-2010 (P<0.001). 
  The proportions of people achieving other lipid targets are shown in Supplementary Table S2. 
There was no significant trend in percentages of people achieving HDL cholesterol target level, 
while the proportions of people achieving triglycerides target level increased significantly from 
45.8% to 57.5% from 1999-2010 (P=0.023).  
 
Discussion 
   The prevalence of diabetes has increased dramatically in the U.S. in the last two decades (18). 
In 2010, about 21 million adult Americans had diagnosed diabetes. Fortunately, recent evidence 
suggested that diabetes-related complications, such as heart attacks, have declined substantially in 
the U.S. (19). Improved control of cardiovascular risk factors might have contributed to the 
decrease in myocardial infarction. Our study generates information on the recent trend of usage of 
different diabetic medications using large and nationally representative multi-stage surveys. 
Favorable trends in controlling glycemia, blood pressure and dyslipidemia might reflect better 
utilization of medications, however from our data greater prevalence of obesity and decreased 
8 
 
prevalence of family history of diabetes were observed in the populations from 1999-2010, and 
these changes should not be neglected as they may also have impact on various risk factors control 
as well. Despite the significant increase in the use of glucose, blood pressure and lipid lowering 
drugs from 1999-2010, about a quarter of the participants achieved all the control targets for 
diabetes. Therefore efforts should be made to look for better treatment and control of diabetes. 
   Although by 2010 more than 80% of diabetes patients have been on glucose lowering 
medications, merely half of them showed good glycemic control (Table 2 and Figure 1a). This 
suggests that there is still improvement to be made in order to enhance the efficacy of the use of 
anti-diabetic drugs. Since 2003, metformin has become the most commonly used glucose lowering 
drug. It is the recommended first line therapy because of its effectiveness in weight reduction, low 
cost and low risk for hypoglycemia (9). Studies also showed reduction in cardiovascular and 
all-cause mortality and reduction in cancer risks with metformin use (20). About half of the people 
taking metformin reached HbA1c control target, which meant that additional diabetic medications 
might be necessary. The use of thiazolidinediones was at a peak during 2003-2006 and the 
percentage of use decreased in 2007-2010. A shift from rosiglitazone to pioglitazone was expected 
during this period, as rosiglitazone was suspected to be associated with myocardial ischemia (21, 
22). Restrictions were made by the FDA in 2010 on the use of rosiglitazone (23), therefore its use of 
rosiglitazone would be expected to decline. 
   The use of DPP-4 inhibitors was first observed in 2007. In our sample population about 33% of 
participants taking the drug could achieve glycemic control, which was less than those taking other 
medications like metformin. This agrees with previous finding that DPP-4 inhibitors could improve 
HbA1c level to a lesser extent than metformin (23). The drug is not widely used for several 
considerations. These agents are not more effective in glucose lowering than other prevalent 
medications; there are also reservations of long-term safety of these agents; these agents are 
expensive and result in greater prescription costs than sulfonylurea and metformin (8). Despite the 
above reservations on DPP-4 inhibitors, a potential advantage of these types of drug is their 
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relatively fewer adverse effects. Compared to sulphonylureas, they cause less hypoglycemia and 
weight gain (24). Such advantage makes this drug attractive to the elderly, especially for those with 
co-morbidities that prevent the use of other medications.    
  Overall more than half of the participants could achieve blood pressure control from 1999-2010, 
and the percentage has been significantly increasing across the period. Also, about 60% of subjects 
taking various anti-hypertensive medications could generally achieve the control targets. 
Considering the various anti-hypertensive medications, there was increasing utilization of ARB, 
diuretics and beta-blockers. In particular, the percentage of subjects using beta-blockers and ARB 
doubled and tripled respectively from 1999-2010. Diuretics and beta-blockers are the traditional 
classes of anti-hypertensive agents. However there has been controversy over the adverse effects of 
these traditional drugs on glucose homeostasis. Beta-blockers and diuretics are generally regarded 
as agents that can increase the risk of new onset diabetes (25). Therefore it has been argued that 
those at risk of developing diabetes should avoid taking beta-blockers and diuretics, though there is 
a debate on the clinical significance of new onset diabetes associated with these drugs (26). The 
increasing use of diuretics and beta-blockers in this study is probably due to the fact that diuretics 
are more commonly used by the elderly while beta-blockers are used to treat hypertensive patients 
with angina. Nevertheless, regular monitoring should be considered to manage the metabolic 
adverse effects at an early stage while maintaining good blood pressure control (27).  
   Statins have been increasingly prescribed in 1999-2010 and more than half of the participants 
were on this class of drugs. Our data shows that there was significant improvement in LDL 
cholesterol control, probably due to the effects of statins and a decline in hypertriglyceridemia. 
There have been discussions on whether statins confer more benefits in diabetic patients, and their 
effects on glycemic control (28, 29). The trend in the use of statins to lower lipid levels is promising, 
while the effect of statins on glycemic control in diabetic patients remains controversial (30). 
However, considering their efficacy in reducing cardiovascular events, stains will remain as one 
common drug class to treat dyslipidemia. 
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In summary, an increasing use of prescription medications for lowering blood glucose, blood 
pressure and LDL-cholesterol were observed over the period of 1999-2010. Metformin and statins 
were the most commonly used medications for lowering blood glucose and lipids respectively, 
whereas DPP-4 inhibitors started to be used since 2007. Usage of ARB, diuretics and beta-blockers 
also increased from 1999-2010. The changing practice in the use of glucose lowering medications 
has resulted in significant increase in glycemic control, whereas more than half of the participants 
could attain good blood pressure control partly due to increased drug prescriptions. Despite the 
slight changes in the characteristics of the US population with type 2 diabetes from 1999 to 2010, 
improvement of risk factor control in recent surveys was associated with increases in prescribed 
medications for lowering blood glucose, lipids and blood pressure and with polypharmacy.  
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Figure Legends 
 
Figure 1. Control rates of treated people with diagnosed diabetes. P value was derived from 
multiple logistic regression models after adjusting for age, sex (except sex-specific estimates) and 
race/ethnicity (except race/ethnicity-specific estimates). *P<0.05, #P<0.01 and ‡P<0.001 
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Table 1. Characteristics of people with diagnosed diabetes in the United States, 1999-2010 
Characteristics 1999-2002 
(n=812) 
2003-2006 
(n=930) 
2007-2010 
(n=1352) 
P for 
trend 
Age (y) 59.1 
(57.8-60.3) 
60.0 
(58.6-61.4) 
60.5 
(59.4-61.5) 
0.093 
Age distribution (%)    0.368 
   20-39 y 8.9 (1.5) 7.3 (1.1) 6.8 (0.7)  
   40-59 y 39.0 (2.1) 41.1 (2.1) 38.4 (1.8)  
   ≥ 60 y 52.1 (2.1) 51.6 (2.5) 54.8 (1.9)  
Women (%) 50.1 (2.1) 54.4 (1.8) 51.6 (2.1)  
Race/Ethnicity (%)‡    0.672 
   Non-Hispanic white 61.4 (3.6) 63.5 (3.1) 60.4 (3.7)  
   Non-Hispanic black 15.5 (2.5) 16.7 (2.2) 18.2 (2.2)  
   Mexican American 6.9 (1.3) 8.1 (1.6) 8.6 (1.9)  
   Other 16.1 (3.8) 11.6 (1.4) 12.9 (1.8)  
Education (%)‡    0.076 
   Less than high school 35.7 (2.3) 29.0 (1.6) 31.8 (1.4) 0.062 
   High school diploma 26.3 (2.3) 26.9 (1.9) 24.0 (2.4) 0.390 
   More than high school 38.0 (2.5) 44.1 (2.7) 44.3 (2.2) 0.032 
Waist circumference (cm) 107.8 
(105.7-109.9) 
109.6 
(107.9-111.4) 
111.2 
(109.0-112.5) 
0.001 
BMI (kg/m
2
) 31.83 
(31.1-32.6) 
32.48 
(31.7-33.3) 
33.32 
(32.7-33.9) 
<0.001 
BMI distribution (%)‡    <0.001 
   < 25.0 kg/m
2
 16.7 (2.0) 13.6 (1.7) 11.2 (1.0)  
   25.0-29.9 kg/m
2
 30.5 (2.2) 28.9 (1.9) 23.5 (1.6)  
   ≥30.0 kg/m2 52.8 (2.8) 57.5 (2.4) 65.3 (1.9)  
HbA1c (%) 7.60 
(7.37-7.82) 
7.14 
(6.99-7.29) 
7.21 
(7.09-7.33) 
0.006 
Blood pressure (mmHg)     
   Systolic 133.0 
(131.1-134.9) 
131.0 
(129.1-132.9) 
128.9 
(127.3-130.5) 
<0.001 
   Diastolic 70.0 
(68.2-71.8) 
68.2 
(66.7-69.7) 
67.4 
(66.0-68.7) 
0.065 
Total cholesterol (mg/dL) 208.2 
(201.7-214.6) 
196.8 
(192.3-201.4) 
183.0 
(179.9-186.1) 
<0.001 
HDL cholesterol (mg/dL) 45.8 
(44.4-47.2) 
50.2 
(48.9-51.5) 
46.7 
(45.7-47.6) 
0.870 
LDL cholesterol (mg/dL)* 117.6 
(114.5-120.8) 
107.8 
(102.7-113.1) 
99.0 
(96.2-101.7) 
<0.001 
Triglycerides (mg/dL)*† 160.9 
(148.3-174.5) 
166.5 
(151.1-183.4) 
133.4 
(125.1-142.3) 
0.002 
Smoking (%)‡    0.992 
   Never 48.7 (2.8) 49.3 (2.2) 48.5 (1.4)  
   Former 32.3 (2.0) 32.6 (1.5) 34.6 (1.4)  
   Current 19.0 (1.6) 18.2 (1.6) 16.9 (1.0)  
Alcohol drinking (%) 12.9 (1.8) 18.3 (1.7) 16.1 (1.5) 0.065 
History of CVD (%)     
   Congestive heart failure 8.4 (1.2) 12.3 (1.1) 10.3 (1.2) 0.519 
   Coronary heart disease 13.0 (1.6) 12.8 (1.5) 12.4 (0.9) 0.532 
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   Angina 11.0 (1.5) 9.9 (1.3) 8.2 (1.1) 0.086 
   Heart attack 11.2 (1.9) 13.0 (1.4) 11.7 (1.0) 0.951 
   Stroke 7.4 (1.1) 10.7 (1.3) 10.4 (1.0) 0.121 
   Any of the above 23.3 (2.2) 31.0 (2.2) 27.9 (1.9) 0.303 
Family history of diabetes (%) 78.6 (1.7) 72.9 (2.5) 68.7 (1.7) <0.001 
Microalbuminuria (%) 35.9 (1.7) 32.2 (2.0) 30.5 (1.5) 0.010 
BMI = body mass index; CVD = cardiovascular disease; HbA1c = glycosylated haemoglobin; HDL 
= high-density lipoprotein; LDL = low-density lipoprotein. 
Data are expressed as percentage or mean (standard error or 95% CI) unless otherwise specified.  
P value was obtained from multiple linear or logistic regression models after adjusting for age 
(except age-specific estimates), sex (except sex-specific estimates) and race/ethnicity (except 
race/ethnicity-specific estimates).  
‡ P values were calculated by ordinal regression after adjusting for age (except age-specific 
estimates), sex (except sex-specific estimates) and race/ethnicity (except race/ethnicity-specific 
estimates). 
*Data were only available in a sub-sample of subjects that had fasted for 8-24 hours (n = 237, 344, 
and 543 for LDL cholesterol, and n = 259, 367, and 566 for triglycerides, in NHANES 1999-2002, 
2003-2006, and 2007-2010 respectively). 
†Data were expressed as geometric mean (95% CI) and log-transformed before analysis. 
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Table 2. Utilization of blood glucose lowering medications among subjects with diagnosed diabetes 
in the United States, 1999-2010 
Characteristics 1999-2002 2003-2006 2007-2010 P for trend 
Metformin 34.8 (2.0) 46.1 (2.8) 53.8 (1.8) <0.001 
Sulfonylureas 41.4 (2.2) 39.8 (2.5) 37.5 (1.6) 0.064 
Thiazolidinediones 12.1 (1.4) 25.9 (1.8) 17.6 (1.2) 0.028 
Insulin 16.3 (2.1) 17.2 (0.9) 20.5 (1.3) 0.085 
Others (including DDP-4 
inhibitors) 
2.4 (0.7) 1.8 (0.5) 11.2 (1.1) <0.001 
DDP-4 inhibitors 0.0 (0.0) 0.0 (0.0) 7.4 (1.1) - 
Polytherapy 27.9 (2.0) 40.7 (2.3) 42.8 (1.6) <0.001 
Any of the above 73.7 (2.3) 77.7 (2.1) 82.1 (1.7) 0.003 
Abbreviation: DPP-4, dipeptidyl peptidase-4. 
P value was derived from multiple logistic regression models after adjusting for age, sex (except 
sex-specific estimates) and race/ethnicity (except race/ethnicity-specific estimates). 
 
 
Table 3. Utilization of blood pressure lowering medications among subjects with diagnosed 
diabetes in the United States, 1999-2010 
Characteristics 1999-2002 2003-2006 2007-2010 P for trend 
ACEI 31.5 (1.8) 40.1 (1.8) 41.2 (1.7) <0.001 
ARB 7.4 (0.8) 14.9 (1.6) 21.4 (1.6) <0.001 
CCB 21.5 (1.9) 19.1 (1.3) 21.0 (1.6) 0.610 
ARA 1.1 (0.5)* 1.3 (0.4)* 2.4 (0.6) 0.101 
-blockers 15.3 (1.9) 26.3 (1.9) 31.8 (1.5) <0.001 
Diuretics 25.8 (2.0) 31.9 (2.0) 36.0 (1.8) 0.001 
Others 10.9 (1.5) 10.1 (1.4) 9.9 (0.7) 0.336 
Polytherapy 34.9 (2.6) 43.2 (1.7) 50.5 (2.0) <0.001 
Any of the above 58.4 (2.3) 70.8 (1.8) 76.9 (1.9) <0.001 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARA, aldosterone receptor 
antagonist; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; 
P value was derived from multiple logistic regression models after adjusting for age, sex (except 
sex-specific estimates) and race/ethnicity (except race/ethnicity-specific estimates). 
*Estimate should be interpreted with caution as coefficient of variation >0.30. 
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Table 4. Utilization of lipid lowering medications among subjects with diagnosed diabetes in the 
United States, 1999-2010 
Characteristics 1999-2002 2003-2006 2007-2010 P for trend 
Statin 28.5 (2.1) 44.8 (2.0) 52.2 (1.4) <0.001 
Fibrate 4.4 (1.0) 4.8 (1.0) 6.6 (1.0) 0.111 
Bile acid sequestrant 0.1 (0.1)* 0.8 (0.5)* 0.5 (0.1)* 0.202 
Nicotinic acid 0.1 (0.2)* 1.1 (0.2) 2.3 (0.5) <0.001 
Cholesterol adsorption 
inhibitor 
0.0 (0.0) 4.2 (0.8) 7.8 (1.3) <0.001 
Others 0.5 (0.0) 0.0 (0.0) 0.1 (0.1)* 0.107 
Polytherapy 1.2 (0.7)* 6.7 (1.1) 11.6 (1.7) <0.001 
Any of the above 32.5 (1.8) 48.6 (2.1) 57.5 (1.5) <0.001 
Abbreviation: LDL, low-density lipoproteins 
P value was derived from multiple logistic regression models after adjusting for age, sex (except 
sex-specific estimates) and race/ethnicity (except race/ethnicity-specific estimates). 
*Estimate should be interpreted with caution as coefficient of variation >0.30. 
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Figure 1.  
(a)  Glycemic control (HbA1c <7.0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *  
 * 
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(b)  Blood pressure control (Blood pressure <140/80 mmHg) 
 
 
(c)  Lipid control (LDL cholesterol <100 mg/dL) 
 
# # # 
# 
‡ 
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Supplementary Table S1. Proportions of people achieving glycemic, blood pressure, and LDL 
cholesterol target levels among those with diagnosed diabetes in the United States, 1999-2010 
Population group 1999-2002 2003-2006 2007-2010 P for trend 
HbA1c <7.0% 
n 775 882 1266 - 
Overall 43.8 (2.8) 58.1 (2.3) 54.0 (2.5) 0.019 
Age     
20-39 years 34.4 (11.0)* 54.3 (7.7) 53.3 (8.3) 0.197 
40-59 years 44.1 (3.9) 51.9 (4.0) 50.6 (4.0) 0.266 
≥60 years 45.2 (3.2) 63.6 (3.0) 56.5 (2.4) 0.020 
Sex     
Men 42.1 (3.0) 55.6 (2.9) 52.4 (3.6) 0.068 
Women 45.6 (3.9) 60.3 (3.0) 55.5 (2.4) 0.060 
Race/ethnicity     
Non-Hispanic white 48.5 (3.9) 64.5 (3.0) 55.6 (3.1) 0.303 
Non-Hispanic black 38.1 (3.5) 44.4 (3.6) 52.2 (2.8) 0.004 
Mexican American 34.0 (3.1) 39.9 (3.4) 42.0 (3.6) 0.211 
Other 35.3 (5.9) 53.9 (7.0) 57.3 (5.6) 0.014 
BMI‡     
<25.0 kg/m
2
 43.5 (6.3) 54.6 (5.3) 60.8 (4.8) 0.045 
25.0-29.9 kg/m
2
 47.8 (5.8) 57.8 (3.8) 60.5 (4.1) 0.057 
≥30.0 kg/m2 41.6 (3.5) 59.1 (2.8) 50.5 (2.8) 0.178 
     
Blood pressure <140/80 mmHg 
n 783 862 830 - 
Overall 55.2 (2.6) 59.4 (2.2) 64.7 (1.9) 0.002 
Age     
20-39 years 50.6 (11.6) 80.2 (5.4) 58.6 (7.4) 0.500 
40-59 years 57.1 (4.4) 56.3 (4.4) 63.6 (3.4) 0.241 
≥60 years 54.5 (2.6) 58.9 (3.2) 66.2 (2.5) 0.002 
Sex     
Men 57.7 (3.1) 63.9 (3.3) 67.1 (3.2) 0.051 
Women 52.6 (4.4) 55.3 (3.3) 62.5 (2.3) 0.033 
Race/ethnicity     
Non-Hispanic white 59.0 (3.7) 60.1 (3.6) 66.1 (3.0) 0.108 
Non-Hispanic black 42.5 (4.4) 58.6 (3.0) 58.0 (2.6) 0.007 
Mexican American 53.6 (3.1) 64.2 (4.5) 65.1 (3.2) 0.012 
Other 53.3 (6.9) 52.9 (6.3) 66.9 (4.7) 0.095 
BMI     
<25.0 kg/m
2
 62.4 (6.5) 62.9 (7.0) 61.6 (5.2) 0.018 
25.0-29.9 kg/m
2
 51.4 (3.8) 57.1 (3.8) 65.5 (3.4) 0.004 
≥30.0 kg/m2 55.0 (4.3) 59.6 (2.6) 65.0 (2.2) 0.026 
     
LDL cholesterol <100 mg/dL 
n 237 344 543 - 
Overall 35.0 (3.9) 46.9 (3.2) 56.5 (2.3) <0.001 
Age     
20-39 years 30.3 (8.2) 45.1 (12.9) 48.3 (11.8) 0.167 
40-59 years 31.2 (5.5) 38.7 (5.4) 46.7 (4.9) 0.030 
≥60 years 40.2 (7.5) 53.5 (3.4) 64.4 (2.7) 0.001 
Sex     
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Men 41.4 (5.3) 52.7 (3.8) 62.1 (3.3) 0.002 
Women 27.3 (4.9) 42.5 (4.4) 51.1 (3.4) 0.001 
Race/ethnicity     
Non-Hispanic white 39.5 (6.0) 48.3 (4.5) 63.3 (3.5) 0.001 
Non-Hispanic black 27.4 (6.4) 51.2 (4.7) 40.8 (5.0) 0.305 
Mexican American 31.3 (6.1) 33.7 (6.0) 45.4 (4.2) 0.092 
Other 26.3 (12.5)* 43.3 (11.1) 50.9 (8.9) 0.237 
BMI     
<25.0 kg/m
2
 29.1 (10.1)* 43.1 (6.4) 60.8 (7.6) 0.031 
25.0-29.9 kg/m
2
 38.9 (7.4) 37.6 (7.0) 56.1 (5.9) 0.065 
≥30.0 kg/m2 34.9 (6.1) 51.9 (3.8) 55.8 (3.3) 0.012 
     
HbA1c <7.0%, blood pressure <140/80 mmHg, and LDL cholesterol <100 mg/dL 
n 231 322 524 - 
Overall 8.7 (1.8) 16.9 (2.9) 24.0 (2.9) <0.001 
Data are expressed as percent (standard error). 
P value was derived from multiple logistic regression models after adjusting for age, sex (except 
sex-specific estimates) and race/ethnicity (except race/ethnicity-specific estimates).   
*Estimate should be interpreted with caution as coefficient of variation >0.30. 
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Supplementary Table S2. Proportions of people achieving other lipid target levels among those 
with diagnosed diabetes in the United States, 1999-2010 
Population group 1999-2002 2003-2006 2007-2010 P for trend 
HDL cholesterol >40 mg/dL in men and >50 mg/dL in women 
n 751 871 1247 - 
Overall 43.2 (2.8) 57.1 (2.2) 48.0 (2.1) 0.506 
Age     
20-39 years 28.9 (5.8) 41.6 (8.0) 46.4 (7.9) 0.067 
40-59 years 44.8 (5.2) 51.6 (3.4) 40.3 (3.0) 0.320 
≥60 years 44.6 (2.6) 63.8 (2.8) 53.6 (2.4) 0.098 
Sex     
Men 48.1 (3.7) 60.4 (3.0) 57.4 (2.4) 0.124 
Women 38.2 (3.4) 54.3 (3.4) 38.9 (2.6) 0.616 
Race/ethnicity     
Non-Hispanic white 40.9 (3.8) 55.5 (3.0) 43.7 (3.0) 0.865 
Non-Hispanic black 52.6 (4.9) 71.3 (3.1) 58.1 (3.1) 0.817 
Mexican American 44.3 (4.5) 51.2 (2.9) 51.5 (3.3) 0.379 
Other 43.5 (6.2) 51.6 (5.8) 52.7 (5.5) 0.287 
BMI     
<25.0 kg/m
2
 61.1 (6.5) 71.3 (5.1) 65.3 (4.6) 0.621 
25.0-29.9 kg/m
2
 46.4 (4.4) 60.1 (3.6) 57.8 (3.5) 0.074 
≥30.0 kg/m2 35.8 (3.8) 52.4 (3.0) 41.4 (2.5) 0.767 
     
Triglycerides <150 mg/dL 
n 259 367 566 - 
Overall 45.8 (3.5) 45.7 (3.2) 57.5 (2.5) 0.023 
Age     
20-39 years 48.7 (8.8) 32.8 (16.1)* 52.5 (11.6) 0.860 
40-59 years 48.3 (6.3) 36.9 (4.7) 54.9 (5.0) 0.399 
≥60 years 42.7 (5.8) 54.8 (4.2) 60.0 (2.8) 0.014 
Sex     
Men 46.5 (4.4) 50.1 (4.4) 58.9 (3.2) 0.066 
Women 45.0 (6.8) 42.4 (4.2) 56.1 (3.8) 0.102 
Race/ethnicity     
Non-Hispanic white 42.5 (4.8) 41.9 (4.4) 55.1 (3.7) 0.022 
Non-Hispanic black 65.3 (8.7) 71.1 (6.0) 73.7 (4.7) 0.603 
Mexican American 37.4 (5.4) 30.2 (6.7) 54.5 (6.0) 0.019 
Other 47.3 (13.1) 39.9 (10.0) 51.1 (6.1) 0.844 
BMI     
<25.0 kg/m
2
 31.9 (8.8) 61.3 (7.5) 75.5 (5.8) 0.001 
25.0-29.9 kg/m
2
 55.6 (6.3) 42.2 (6.8) 62.3 (4.9) 0.488 
≥30.0 kg/m2 45.1 (5.5) 43.5 (4.4) 52.1 (2.9) 0.359 
Data are expressed as percent (standard error).   
P value was derived from multiple logistic regression models after adjusting for age, sex (except 
sex-specific estimates) and race/ethnicity (except race/ethnicity-specific estimates).   
*Estimate should be interpreted with caution as coefficient of variation >0.30. 
 
 
